Literature DB >> 21441532

Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with 123I-metaiodobenzylguanidine in chronic Chagas cardiomyopathy.

Carlos H Miranda1, Alexandre B Figueiredo, Benedito C Maciel, José Antônio Marin-Neto, Marcus Vinícius Simões.   

Abstract

UNLABELLED: Cardiac sympathetic denervation and ventricular arrhythmia are frequently observed in chronic Chagas cardiomyopathy (CCC). This study quantitatively evaluated the association between cardiac sympathetic denervation and sustained ventricular tachycardia (SVT) in patients with CCC.
METHODS: We prospectively investigated patients with CCC and left ventricular ejection fraction (LVEF) greater than 35% with SVT (SVT group: n = 15; mean age ± SD, 61 ± 8 y; LVEF, 51% ± 8%) and patients without SVT (non-SVT group: n = 11; mean age ± SD, 55 ± 10 y; LVEF, 57% ± 10%). Patients underwent myocardial scintigraphy with (123)I-metaiodobenzylguanidine ((123)I-MIBG) for the evaluation of sympathetic innervation and resting perfusion with (99m)Tc-methoxyisobutylisonitrile ((99m)Tc-MIBI) for the evaluation of myocardial viability. A visual semiquantitative score was attributed for regional uptake of each radiotracer using a 17-segment left ventricular segmentation model (0, normal; 4, absence of uptake). A mismatch defect was defined as occurring in segments with a (99m)Tc-MIBI uptake score of 0 or 1 and a (123)I-MIBG score of 2 or more.
RESULTS: Compared with the non-SVT group, the SVT group had a similar (99m)Tc-MIBI summed score (6.9 ± 7.5 vs. 4.4 ± 5.2, respectively, P = 0.69) but a higher (123)I-MIBG summed score (10.9 ± 7.8 vs. 22.4 ± 9.5, respectively, P = 0.007) and a higher number of mismatch defects per patient (2.0 ± 2.2 vs. 7.1 ± 2.0, respectively, P < 0.0001). The presence of more than 3 mismatch defects was strongly associated with the presence of SVT (93% sensitivity, 82% specificity; P = 0.0002).
CONCLUSION: In CCC, the amount of sympathetically denervated viable myocardium is associated with the occurrence of SVT. Myocardial sympathetic denervation may participate in triggering malignant ventricular arrhythmia in CCC patients with relatively well-preserved ventricular function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441532     DOI: 10.2967/jnumed.110.082032

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

Review 1.  Current Clinical Applications and Next Steps for Cardiac Innervation Imaging.

Authors:  Mark I Travin
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

2.  ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.

Authors:  Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-06       Impact factor: 5.952

3.  Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: Development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT.

Authors:  Ian P Clements; Ernest V Garcia; Ji Chen; Russell D Folks; Javed Butler; Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2015-03-19       Impact factor: 5.952

4.  The long way to defeating Chagas cardiomyopathy.

Authors:  Mario Petretta; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2018-02-21       Impact factor: 5.952

5.  The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy : Chagas disease, denervation and arrhythmia.

Authors:  Leonardo Pippa Gadioli; Carlos Henrique Miranda; Antonio Osvaldo Pintya; Alexandre Baldini de Figueiredo; André Schmidt; Benedito Carlos Maciel; José Antonio Marin-Neto; Marcus Vinicius Simões
Journal:  J Nucl Cardiol       Date:  2016-07-05       Impact factor: 5.952

Review 6.  Cardiac Sympathetic Denervation for the Management of Ventricular Arrhythmias.

Authors:  Stephanie M Kochav; Hasan Garan; Lyall A Gorenstein; Elaine Y Wan; Hirad Yarmohammadi
Journal:  J Interv Card Electrophysiol       Date:  2022-04-09       Impact factor: 1.900

Review 7.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

Review 8.  Cardiac autonomic imaging with SPECT tracers.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2013-02       Impact factor: 5.952

Review 9.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

Review 10.  Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.

Authors:  Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina
Journal:  Pathogens       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.